Published in J Natl Cancer Inst on April 19, 2006
Effects of Testosterone Treatment in Older Men. N Engl J Med (2016) 6.66
An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J Natl Cancer Inst (2011) 5.73
Integrating the predictiveness of a marker with its performance as a classifier. Am J Epidemiol (2007) 4.59
Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms. Ann Intern Med (2013) 4.45
Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ (2010) 4.42
Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol (2008) 4.02
Can urinary PCA3 supplement PSA in the early detection of prostate cancer? J Clin Oncol (2014) 3.64
Evaluating the predictiveness of a continuous marker. Biometrics (2007) 3.54
Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncol (2014) 3.04
Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Clin Oncol (2009) 2.95
The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. Clin Cancer Res (2010) 2.87
Genetic correction of PSA values using sequence variants associated with PSA levels. Sci Transl Med (2010) 2.83
Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer. Urology (2014) 2.62
Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med (2011) 2.62
The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. Cancer (2012) 2.61
Prospective evaluation of operating characteristics of prostate cancer detection biomarkers. J Urol (2010) 2.54
Prospective study of Trichomonas vaginalis infection and prostate cancer incidence and mortality: Physicians' Health Study. J Natl Cancer Inst (2009) 2.50
Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trial. Eur Urol (2012) 2.34
Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort. Eur Urol (2009) 2.31
Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion. J Clin Oncol (2012) 2.28
Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. Eur Urol (2015) 2.20
Predicting risk of prostate cancer in men receiving finasteride: effect of prostate volume, number of biopsy cores, and American Urological Association symptom score. Urology (2013) 2.06
Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy. J Clin Oncol (2009) 2.05
The Memorial Sloan Kettering Cancer Center Recommendations for Prostate Cancer Screening. Urology (2016) 2.05
The benefits and risks of testosterone replacement therapy: a review. Ther Clin Risk Manag (2009) 1.90
A parametric ROC model-based approach for evaluating the predictiveness of continuous markers in case-control studies. Biometrics (2009) 1.79
Risk-based prostate cancer screening. Eur Urol (2011) 1.64
Focusing PSA testing on detection of high-risk prostate cancers by incorporating patient preferences into decision making. JAMA (2014) 1.60
Semiparametric methods for evaluating risk prediction markers in case-control studies. Biometrika (2009) 1.57
Validation of biomarker-based risk prediction models. Clin Cancer Res (2008) 1.57
The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men. Eur Urol (2014) 1.57
Critical review of prostate cancer predictive tools. Future Oncol (2009) 1.57
Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol (2008) 1.55
Yearly prostate specific antigen and digital rectal examination fluctuations in a screened population. J Urol (2009) 1.55
Body mass index adjusted prostate-specific antigen and its application for prostate cancer screening. Urology (2010) 1.53
A Perturbation Method for Inference on Regularized Regression Estimates. J Am Stat Assoc (2012) 1.53
Testing for the recurrent HOXB13 G84E germline mutation in men with clinical indications for prostate biopsy. J Urol (2012) 1.52
The Prostate Cancer Prevention Trial risk calculator and the relationship between prostate-specific antigen and biopsy outcome. Cancer (2013) 1.52
The prostate cancer risk calculator from the Prostate Cancer Prevention Trial underestimates the risk of high grade cancer in contemporary referral patients. J Urol (2010) 1.50
Prostate-specific antigen: a misused and maligned prostate cancer biomarker. J Natl Cancer Inst (2008) 1.49
Biomarkers in prostate cancer surveillance and screening: past, present, and future. Ther Adv Urol (2013) 1.48
Sixteen-year longitudinal changes in serum prostate-specific antigen levels: the olmsted county study. Mayo Clin Proc (2012) 1.46
Germline BRCA1 mutations increase prostate cancer risk. Br J Cancer (2012) 1.45
Digital rectal examination in primary care is important for early detection of prostate cancer: a retrospective cohort analysis study. Br J Gen Pract (2014) 1.44
Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. World J Urol (2011) 1.42
An examination of the dynamic changes in prostate-specific antigen occurring in a population-based cohort of men over time. BJU Int (2012) 1.42
Development and External Validation of the Korean Prostate Cancer Risk Calculator for High-Grade Prostate Cancer: Comparison with Two Western Risk Calculators in an Asian Cohort. PLoS One (2017) 1.38
Race, genetic West African ancestry, and prostate cancer prediction by prostate-specific antigen in prospectively screened high-risk men. Cancer Prev Res (Phila) (2009) 1.36
Tumor markers in prostate cancer I: blood-based markers. Acta Oncol (2011) 1.28
Novel biomarkers for prostate cancer including noncoding transcripts. Am J Pathol (2009) 1.25
Traditional statistical methods for evaluating prediction models are uninformative as to clinical value: towards a decision analytic framework. Semin Oncol (2010) 1.25
A clinical risk prediction model for Barrett esophagus. Cancer Prev Res (Phila) (2012) 1.21
Transition of a clinical trial into translational research: the prostate cancer prevention trial experience. Cancer Prev Res (Phila) (2010) 1.17
Predicting the outcome of prostate biopsy: comparison of a novel logistic regression-based model, the prostate cancer risk calculator, and prostate-specific antigen level alone. BJU Int (2008) 1.17
A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands. Br J Cancer (2010) 1.16
Statistical methods to correct for verification bias in diagnostic studies are inadequate when there are few false negatives: a simulation study. BMC Med Res Methodol (2008) 1.14
Prostate kallikrein markers in diagnosis, risk stratification and prognosis. Nat Rev Urol (2009) 1.13
Risk stratification in prostate cancer screening. Nat Rev Urol (2012) 1.13
Prostate-specific antigen in the early detection of prostate cancer. CMAJ (2007) 1.13
Overdiagnosis of prostate cancer. J Natl Cancer Inst Monogr (2012) 1.11
Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen. BMC Med (2014) 1.11
Clinically localised prostate cancer. BMJ (2006) 1.11
Screening for prostate cancer: an update. Can J Urol (2008) 1.11
Estimating the capacity for improvement in risk prediction with a marker. Biostatistics (2008) 1.08
Updating risk prediction tools: a case study in prostate cancer. Biom J (2011) 1.08
Simulation optimization of PSA-threshold based prostate cancer screening policies. Health Care Manag Sci (2012) 1.06
Raising cut-off value of prostate specific antigen (PSA) for biopsy in symptomatic men in India to reduce unnecessary biopsy. Indian J Med Res (2014) 1.06
Prostate cancer risk assessment tools in an unscreened population. World J Urol (2014) 1.05
External validation of the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer risk calculators in a Chinese cohort. Asian J Androl (2012) 1.05
Patient preference and the impact of decision-making aids on prostate cancer treatment choices and post-intervention regret. Curr Oncol (2012) 1.03
Clinical collection and protein properties of expressed prostatic secretions as a source for biomarkers of prostatic disease. J Proteomics (2009) 1.03
Relationship between initial PSA density with future PSA kinetics and repeat biopsies in men with prostate cancer on active surveillance. Prostate Cancer Prostatic Dis (2010) 1.02
Hormone replacement therapy and physical function in healthy older men. Time to talk hormones? Endocr Rev (2012) 1.01
Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group. World J Urol (2011) 1.00
Body composition and serum prostate-specific antigen: review and findings from Flint Men's Health Study. Urology (2008) 0.99
Results of a Randomized Clinical Trial of the Action of Several Doses of Lycopene in Localized Prostate Cancer: Administration Prior to Radical Prostatectomy. Clin Med Urol (2008) 0.99
Assessing risk prediction models in case-control studies using semiparametric and nonparametric methods. Stat Med (2010) 0.98
Prostate cancer risk-associated genetic markers and their potential clinical utility. Asian J Androl (2013) 0.97
CCL11 (eotaxin-1): a new diagnostic serum marker for prostate cancer. Prostate (2012) 0.97
Optimization of PSA screening policies: a comparison of the patient and societal perspectives. Med Decis Making (2011) 0.96
Emergence of ETS transcription factors as diagnostic tools and therapeutic targets in prostate cancer. Am J Transl Res (2013) 0.96
Plateau effect of prostate cancer risk-associated SNPs in discriminating prostate biopsy outcomes. Prostate (2013) 0.96
Does the level of prostate cancer risk affect cancer prevention with finasteride? Urology (2008) 0.95
Evaluating the Prostate Cancer Prevention Trial High Grade Prostate Cancer Risk Calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. World J Urol (2012) 0.94
Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada. Int J Cancer (2014) 0.94
Racial differences in prostate cancer screening by family history. Ann Epidemiol (2008) 0.94
A nomogram based on age, prostate-specific antigen level, prostate volume and digital rectal examination for predicting risk of prostate cancer. Asian J Androl (2012) 0.94
Should Canadians be offered systematic prostate cancer screening? Yes. Can Fam Physician (2007) 0.93
A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result. Prostate Cancer Prostatic Dis (2015) 0.93
The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements. Biomark Cancer (2016) 0.92
Risk factor stratification after simultaneous liver and colorectal resection for synchronous colorectal metastasis. Langenbecks Arch Surg (2007) 0.91
PSA Velocity and Doubling Time in Diagnosis and Prognosis of Prostate Cancer. Br J Med Surg Urol (2012) 0.89
Obesity and prostate cancer detection: insights from three national surveys. Am J Med (2010) 0.89
Making sense of cancer risk calculators on the web. J Gen Intern Med (2008) 0.89
Validation of proposed prostate cancer biomarkers with gene expression data: a long road to travel. Cancer Metastasis Rev (2014) 0.89
The influence of finasteride on the development of prostate cancer. N Engl J Med (2003) 24.45
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med (2004) 23.44
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med (2004) 15.10
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2008) 13.35
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst (2005) 13.00
Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med (2003) 11.35
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med (2003) 11.25
Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2011) 11.02
Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J Natl Cancer Inst (2013) 10.30
Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med (2013) 7.53
Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA (2006) 7.20
Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res (2002) 7.11
Association between body-mass index and risk of death in more than 1 million Asians. N Engl J Med (2011) 6.89
Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. Lancet (2012) 6.79
Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst (2008) 6.79
Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol (2007) 6.73
Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA (2005) 6.50
Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res (2008) 6.47
Erectile dysfunction and subsequent cardiovascular disease. JAMA (2005) 6.22
Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med (2013) 6.17
An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J Natl Cancer Inst (2011) 5.73
Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. J Natl Cancer Inst (2009) 5.62
CBP/p300-mediated acetylation of histone H3 on lysine 56. Nature (2009) 4.83
Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2007) 4.64
Integrating the predictiveness of a marker with its performance as a classifier. Am J Epidemiol (2007) 4.59
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50
Accuracy of screening mammography interpretation by characteristics of radiologists. J Natl Cancer Inst (2004) 4.07
Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2006) 4.02
Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res (Phila) (2008) 3.99
Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol (2006) 3.81
Molecular characterization of human prostate carcinoma cell lines. Prostate (2003) 3.81
Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst (2006) 3.63
Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst (2006) 3.62
Evaluating the predictiveness of a continuous marker. Biometrics (2007) 3.54
Protein kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen. Arch Gen Psychiatry (2008) 3.28
Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem (2002) 3.05
Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst (2005) 2.99
Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol (2007) 2.97
Estimated impact of the Prostate Cancer Prevention Trial on population mortality. Cancer (2005) 2.91
Lung cancer risk among female textile workers exposed to endotoxin. J Natl Cancer Inst (2007) 2.87
5-year urinary and sexual outcomes after radical prostatectomy: results from the prostate cancer outcomes study. J Urol (2005) 2.72
Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res (2013) 2.70
A data-analytic strategy for protein biomarker discovery: profiling of high-dimensional proteomic data for cancer detection. Biostatistics (2003) 2.69
Neutrophil-independent mechanisms of caspase-1- and IL-18-mediated ischemic acute tubular necrosis in mice. J Clin Invest (2002) 2.65
Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol (2011) 2.57
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol (2012) 2.51
Optimizing bladder cancer locoregional failure risk stratification after radical cystectomy using SWOG 8710. Cancer (2014) 2.48
Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention. Cancer Prev Res (Phila) (2008) 2.43
SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin Chem (2007) 2.38
A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev (2010) 2.36
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol (2013) 2.29